Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
提供了一种作为CCR1受体强效
拮抗剂的化合物,已经在动物炎症测试中进一步确认,这是CCR1标志性疾病状态之一。这些化合物通常是芳基
哌嗪衍
生物,可用于制药组合物、治疗CCR1介导疾病的方法,以及用作竞争性CCR1
拮抗剂鉴定的控制物。